Tachyphylaxis to local anaesthetics. What is the clinical evidence? A systematic review

2015 ◽  
Vol 60 (1) ◽  
pp. 6-14 ◽  
Author(s):  
U. E. Kongsgaard ◽  
M. U. Werner
2020 ◽  
Vol 16 ◽  
Author(s):  
Mariam Ahmed Saad ◽  
Mostafa Alfishawy ◽  
Mahmoud Nassar ◽  
Mahmoud Mohamed ◽  
Ignatius N Esene ◽  
...  

Introduction: Over 4.9 million cases of Coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide pandemic began. Since the emergence of COVID-19, a number of confirmed cases reported autoimmune manifestations. Herein, we reviewed the reported COVID-19 cases with associated autoimmune manifestations. Methods: We searched PubMed database using all available keyword for COVID-19. All related studies between January 1st, 2020 to May 22nd, 2020 were reviewed. Only studies published in English language were considered. Articles were screened based on titles and abstract. All reports of confirmed COVID-19 patients who have associated clinical evidence of autoimmune disease were selected. Results: Among 10006 articles, searches yielded, Thirty-two relevant articles for full-text assessment. Twenty studies meet the eligibility criteria. The twenty eligible articles reported 33 cases of confirmed COVID-19 diagnosis who developed an autoimmune disease after the onset of covid-19 symptoms. Ages of patients varied from a 6 months old infant to 89 years old female (Mean=53.9 years of 28 cases); five cases had no information regarding their age. The time between symptoms of viral illness and onset of autoimmune symptoms ranged from 2 days to 33 days (Mean of the 33 cases=9.8 days). Autoimmune diseases were one case of subacute thyroiditis (3%), two cases of Kawasaki Disease (6.1%), three cases of coagulopathy and antiphospholipid syndrome (9.1%), three cases of immune thrombocytopenic purpura (9.1%), eight cases of autoimmune hemolytic anemia (24.2%), and sixteen cases of Guillain–Barré syndrome (48.5%). Conclusions: COVID-19 has been implicated in the development in a range of autoimmune diseases which may shed a light on the association between autoimmune diseases and infections.


Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 351
Author(s):  
Massimiliano Creta ◽  
Giuseppe Celentano ◽  
Luigi Napolitano ◽  
Roberto La Rocca ◽  
Marco Capece ◽  
...  

Bladder cancer (BCa) is an endocrine-related tumour and the activation of androgen signalling pathways may promote bladder tumorigenesis. We summarized the available preclinical and clinical evidence on the implications of the manipulation of androgen signalling pathways on the outcomes of BCa therapies. A systematic review was performed in December 2020. We included papers that met the following criteria: original preclinical and clinical research; evaluating the impact of androgen signalling modulation on the outcomes of BCa therapies. Six preclinical and eight clinical studies were identified. The preclinical evidence demonstrates that the modulation of androgen receptor-related pathways has the potential to interfere with the activity of the Bacillus Calmette Guerin, doxorubicin, cisplatin, gemcitabine, and radiotherapy. The relative risk of BCa recurrence after transurethral resection of the bladder tumour (TURBT) is significantly lower in patients undergoing therapy with 5 alpha reductase inhibitors (5-ARIs) or androgen deprivation therapy (ADT) (Relative risk: 0.50, 95% CI: 0.30–0.82; p = 0.006). Subgroup analysis in patients receiving 5-ARIs revealed a relative risk of BCa recurrence of 0.46 (95% CI: 0.22–0.95; p = 0.040). A significant negative association between the ratio of T1 BCa patients in treated/control groups and the relative risk of BCa recurrence was observed. Therapy with 5-ARIs may represent a potential strategy aimed at reducing BCa recurrence rate, mainly in patients with low stage disease. Further studies are needed to confirm these preliminary data.


Cartilage ◽  
2019 ◽  
pp. 194760351985240 ◽  
Author(s):  
Luca Andriolo ◽  
Davide Reale ◽  
Alessandro Di Martino ◽  
Angelo Boffa ◽  
Stefano Zaffagnini ◽  
...  

2016 ◽  
Vol 45 (7) ◽  
pp. 842-850 ◽  
Author(s):  
P. Altuna ◽  
E. Lucas-Taulé ◽  
J. Gargallo-Albiol ◽  
O. Figueras-Álvarez ◽  
F. Hernández-Alfaro ◽  
...  

2019 ◽  
Vol 35 (1) ◽  
pp. 251-259 ◽  
Author(s):  
Christopher J. Hadley ◽  
Weilong J. Shi ◽  
Hamadi Murphy ◽  
Fotios P. Tjoumakaris ◽  
John P. Salvo ◽  
...  

2013 ◽  
Vol 15 (4) ◽  
pp. 497-502 ◽  
Author(s):  
Jia-Dong Xia ◽  
You-Feng Han ◽  
Liu-Hua Zhou ◽  
Yun Chen ◽  
Yu-Tian Dai

2017 ◽  
Vol 32 (1) ◽  
pp. 3-18 ◽  
Author(s):  
Karen Savage ◽  
Joseph Firth ◽  
Con Stough ◽  
Jerome Sarris

Sign in / Sign up

Export Citation Format

Share Document